The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

The company is not profitable yet but is guiding to be profitable in 2024. And revenue is increasing at an impressive pace. The stock doesn't get much analyst attention, but the four analysts that have issued a rating give MVST a consensus price target of $4.50, an 857% gain from its closing price on June 12, 2024. Source: PopTika / Shutterstock.com But all it takes is one. And that's also the number of candidates in Gossamer Bio's pipeline. The company has a candidate, Seralutinib (GB002), in a Phase 3 cli ...